MSDS Cryopreserved Cells
Cell Apps Flyer Skeletal System Cells
5 Important Cell Culture Rules
Cell Apps Poster Primary Cells
Human Fibroblast-Like Synoviocytes: Rheumatoid Arthritis (HFLS-RA) provide an excellent cellular model for studying synoviocyte physiology in relation to development and treatment of rheumatoid arthritis.
HFLS-RA from Cell Applications, Inc. have been used in research to evaluate:
- Signaling pathways implicated in the development of joint inflammation and rheumatoid arthritis
- Contribution of EBV to nonresolving rheumatoid arthritis inflammation through inducing IL-6 production by synoviocytes
- Anti-inflammatory and antirheumatic activity of various compounds, such as celastrol, triptolide, arsenic trioxide, bucillamine, therapeutic lyposomes, anti-IL-6R and anti-CD319 antibodies, inhibitors of NF-κB, methionine aminopeptidase-2, Tpl2, aryl hydrocarbon receptor, p38 MAP kinase
- Beneficial anti-inflammatory effects of low level light therapy
- Causes of metalloproteinase induction in patients with Lyme disease-associated arthritis
- Adenovirus-based siRNA delivery systems
- Causative agents, immunopathological mechanisms and signal transduction pathways leading to joint inflammation in rheumatoid arthritis
- The role of estrogen signaling in increasing inflammation
- Anti-inflammatory properties of herbal compound Sinomenine suggested for rheumatoid arthritis treatment
- Effects of extracellular matrix composition on cell attachment and migration relevant to T-cell function in inflamed tissues
- Involvement of capsid proteins of parvorvirus B19 in activating synoviocyte migration and induction of the inflammatory response leading to acute symmetrical polyarthropathy
- The role of human endogenous retroviruses (HERVs) in development of rheumatoid arthritis, and suggest that activated expression of different forms of HERV contribute to development of rheumatoid arthritis symptoms by different mechanisms
Human synovial tissue from donor w/ rheumatoid arthritis
No bacteria, yeast, fungi, mycoplasma, virus
500,000 HFLS-RA frozen in Basal Medium w/ 10% FBS, 10% DMSO
Cryovial frozen HFLS-RA (408RA-05a), Gr Med (415-500), Subcltr Rgnt Kit (090K)
Shipped in Gr Med, 3rd psg (flasks or plates)
|At least 5|
|Laboratory research use only (RUO). Not for human, clinical, diagnostic or veterinary use.|
|Cryopreserved HFLS-RA, Adult: 5x10^5 Cells (from donor with Rheumotoid Arthritis, Adult), Medium & Subculture Reagents (See Details tab for specifics)||Size: 1 Kit||CAT.#: 408RAK-05a||Price: $895.00|
|Cryopreserved HFLS-RA, Adult: Frozen HFLS from donor with Rheumotoid Arthritis (5x10^5)||Size: 1 Cryovial||CAT.#: 408RA-05a||Price: $748.00|
|Proliferating HFLS-RA, Adult: Actively growing, dividing cells in medium, from donor with Rheumotoid Arthritis||Size: T-25 Flask||CAT.#: 409RA-25a||Price: $748.00|
|Proliferating HFLS-RA, Adult: Actively growing, dividing cells in medium, from donor with Rheumotoid Arthritis||Size: T-75 Flask||CAT.#: 409RA-75a||Price: $952.00|
|Proliferating HFLS-RA, Adult: Actively growing, dividing cells in medium, from donor with Rheumotoid Arthritis||Size: 6 Well||CAT.#: 409RA-6Wa||Price: $914.00|
|Size: 96 Well||CAT.#: 409RA-96Wa||Price: $1,043.00|
|HFLS Basal Medium: Basal medium (contains no growth supplement). Add GS before use.||Size: 500 ml||CAT.#: 414-500||Price: $54.00|
|HFLS Growth Medium wo Antibiotics: Growth medium without antibiotics||Size: 500 ml||CAT.#: 415A-500||Price: $111.00|
|HFLS Growth Medium wo FBS: Growth medium without FBS||Size: 500 ml||CAT.#: 415F-500||Price: $111.00|
|HFLS Growth Medium: All-in-one ready-to-use||Size: 500 ml||CAT.#: 415-500||Price: $102.00|
|HFLS Growth Medium Kit: Basal medium & growth supplement sold together packaged separately||Size: Yields 500 ml||CAT.#: 415K-500||Price: $111.00|
|HFLS Growth Supplement: Added to Basal Medium to create Growth Medium||Size: 50 ml||CAT.#: 415-GS||Price: $57.00|
|Subculture Reagent Kit: 100 ml each of HBSS, Trypsin/EDTA & Trypsin Neutralizing Solution||Size: 1 Kit||CAT.#: 090K||Price: $55.00|
Extended Family Products
|HFLS-RA RNA, Adult: Total RNA prepared from Human Fibroblast-Like Synoviocytes-Rheumatoid Arthritis, adult||Size: 10 ug||CAT.#: 408RA-R10a||Price: $350.00|
|HFLS-RA RNA, Adult: Total RNA prepared from Human Fibroblast-Like Synoviocytes-Rheumatoid Arthritis, adult||Size: 25 ug||CAT.#: 408RA-R25a||Price: $700.00|
Jones, D., A. Jenny, J. Swantek, J. Burke, D. Lauffenburger and P. Sorger. 2017. Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation. Nature Chem Biol, 13:38-45.
Yao, Y., C. Jiang, N. Sun, W. Li, Y. iu, H. Han, Z. Miao, X. Zhao, J. Zhao and J. Li. 2017. Tamaractam, a New Bioactive Lactam from Tamarix ramosissima, Induces Apoptosis in Rheumatoid Arthritis Fibroblast-Like Synoviocytes. Molecules 22:96.
Jin, L., Y. Nonaka, S. Miyakawa, M. Fujiwara and Y. Nakamura. 2016. Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain. Mole Ther, 24:1974-1986.
Jones, D., A. Jenny, J. Swantek, J. Burke, D. Lauffenburger and P. Sorger. 2016. Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation. Nature Chemical Biology, doi:10.1038/nchembio.2211.
Lauzier, A., R. Lavoie, M. Charbonneau, B. Gouin-Boisvert, K. Harper, and C. Dubois. 2015 Snail Is a Critical Mediator of Invadosome Formation and Joint Degradation in Arthritis. Am J Pathol, 186:359-374.
Sable, R., T. Durek, V. Taneja, D. Craik, S. Pallerla, S. Pallerla, T. Gautheir and S. Jois. 2016. Constrained Cyclic Peptides as Immunomodulatory Inhibitors of the CD2:CD58 Protein–Protein Interaction. ACS Chem Biol, 11:2366–2374.
Shekhani, M., T. Forde, A. Adilbayeva, M. Ramez, A. Myngbay, Y. Bexeitov, V. Lindner and M. Ramez. 2016. Collagen triple helix repeat containing 1 is a new promigratory marker of arthritic pannus. Arthritis Research & Therapy, 18:171.
Tan, L., D. Gurbani, E. Weisberg, D. Jones, S. Rao, W. Singer, F. Bernard, S. Mowafy, A. Jenney, G. Du, A. Nonami, J. Griffin, D. Lauffenburger, K. Westover, P. Sorger and N. Gray. 2016. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorganic & Med Chem, dx.doi.org/10.1016/j.bmc.2016.11.034.
Auer, J. M. Bader, J. Fischer, H. Kettenberger, M. Hilger, S. Lorenz, and J. Moelleken. 2015. BISPECIFIC ANTIBODIES AGAINST HUMAN TWEAK AND HUMAN 1L17 AND USES THEREOF. Patent Application 20150132307 A1.
Calabro, A., M. Lauer, and V. Hascall. 2015. Treatment of extracellular matrix to reduce inflammation. Patent US 9012395 B2.
Chen, H., J. Pan, J. Wang, Q. Liao, and X. Xia. 2015. Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Induces Apoptosis in Rheumatoid Arthritis Fibroblast-Like Synoviocytes. Inflammation, 10.1007/s10753-015-0220-3.
Fuji, S., K. Fujimoto, N. Goto, M. Kanawa, T. Kawamoto, H. Pan, P. Srivatanakul, W. Rakdang, J. Pornprsitwech, T. Saskianti, K. Suardita, F. Nishimura, and Y. Kato. 2015. Characteristic expression of MSX1, MSX2, TBX2 and ENTPD1 in dental pulp cells. Biomedical Reports, 29 April.
Fujii, W., Y. Kawahito, H. Nagahara, Y. Kukida, T. Seno, A. Yamamoto, M. Kohno, R. Oda, D. Taniguchi, H. Fujiwara, A. Ejima, T. Kishida, O. Mazda, and E. Ashihara. 2015. Monocarboxylate transporter 4, associated with the acidification of synovial fluid, is a novel therapeutic target for inflammatory arthritis. Arthritis & Rheumatology, DOI: 10.1002/art.39270.
Jie, L., R.Huang, W. Sun, S. Wei, Y. Chu, Q. Huang, and H. Du. 2015. Role of cysteine‑rich angiogenic inducer 61 in fibroblast‑like synovial cell proliferation and invasion in rheumatoid arthritis. Molecular Medicine Reports, 11:917-923.
Lauzier, A., R. Lavoie, M. Charbonneau, B. Gouin-Boisvert, K. Harper, and C. Dubois. 2015. Snail Is a Critical Mediator of Invadosome Formation and Joint Degradation in Arthritis. Am J Pathol, http://dx.doi.org/10.1016/j.ajpath.2015.10.021.
Lee, F., J. Lim, M. Reithofer, S. Lee, J. Chung, C. Hauser, and M. Kurisawa. 2015. Synthesis and bioactivity of a conjugate composed of green tea catechins and hyaluronic acid. Polymer Chemistry, 6:4462-4472.
McCoy, J., D. Walkenhorst, K. McCauley, H. Elaasar, J. Everett, and K. Mix. 2015. Orphan nuclear receptor NR4A2 induces transcription of the immunomodulatory peptide hormone prolactin. Journal of Inflammation, 12:13.
Tsushima, H., K. Okazaki, K. Ishihara, T. Ushijima and Y. Iwamoto. 2015. CCAAT/enhancer-binding protein β promotes receptor activator of nuclear factor-kappa-B ligand (RANKL) expression and osteoclast formation in the synovium in rheumatoid arthritis. Arthritis Res & Ther, 17:31.
Yoshioka, R.0, Y. Kita, A. Nagahira, A. Manno, N. Makita, U. Tomita, and M. Murakawa. 2015. Quantitative analysis of cadherin-11 and β-catenin signalling during proliferation of rheumatoid arthritis-derived synovial fibroblast cells. Journal of Pharmacy and Pharmacology, 18 March.
Zhang, W., Z. Du, J. Zhu, J. Yu and Y. Xu. 2015. Sprouty2 suppresses the inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes through regulating the Raf/ERK and PTEN/AKT signals. Molec Immunol, 67:532-539.
Zhang, Y. and B. Zhang. 2015. Trichostatin A, an Inhibitor of Histone Deacetylase, Inhibits the Viability and Invasiveness of Hypoxic Rheumatoid Arthritis Fibroblast-Like Synoviocytes via PI3K/Akt Signaling. J Biochem Mol Toxicol, 30:163-169. HFLS-RA
Allan, B., A. Glasebrook, J. Lu, Y. Tang, D. Witcher, D. Leung, P. Yachi, and A. Vendel. 2014.Anti-tnf-anti-il-17 bispecific antibodies. Patent Application US 20140255406 A1.
Brys, R. and Vandeghinste, N. 2014. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases. Patent US 8637257 B2.
Brys, R., N. Vandeghinste, P. Tomme, and H. Klaassen. 2014. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases. Patent US 8673268 B2.
Calabro, A., M. Lauer, and V. Hascall. 2014. Treatment of extracellular matrix to reduce inflammation. Patent US 8658593 B2.
Fouser, L. M. Hegen, D. Luxenberg and M. O’Toole. 2014. Methods of using antibodies against human IL-22. Patent US 8906375 B2.
Hashizume, M. and M. Mihara. 2014. Combination of High-Molecular-Weight Hyaluronic Acid and Cytokine Inhibitor Potently Inhibits Expression of Joint-Damage-Related Genes Induced By Synovial Fluid of RA Patients. J Arthritis, 3:1.
Jie, L., H. Du, Q. Huang, W. Wei, R. Huang, and W. Sun. 2014. Tanshinone IIA Induces Apoptosis in Fibroblast-Like Synoviocytes in Rheumatoid Arthritis via Blockade of the Cell Cycle in the G2/M Phase and a Mitochondrial Pathway. Biological and Pharmaceutical Bulleting 37:1366-1372.
Lahoti, T. 2014. ARYL HYDROCARBON RECEPTOR ANTAGONISM ALTERS PHENOTYPE OF PRIMARY HUMAN FIBROBLAST-LIKE SYNOVIOCYTE FROM RHEUMATOID ARTHRITIS PATIENTS. Penn State, PhD Dissertation.
Wang, H., H. Wang, S. Huang, H. Zhao, Y. Cao, G. Wang, D. Wang, Z. Wang, and Y. Liu. 2014. Inhibitory effect of baicalin on collagen-induced arthritis in rats through the nuclear factor–κB pathway. JPET 350:435-443.
Chiu, W.-C., C.-M. Chen, T.-T. Cheng, H.-L. You, S.-F. Yu, L.-H. Weng, H.-Y. Huang, C.-C. Huang, and C.-J. Chen. 2013. EBV-encoded small RNA1 and nonresolving inflammation in rheumatoid arthritis. The Kaohsiung Journal of Medical Sciences. 29:606-610.
Fan, C., D. Rajasekaran, M.A. Syed, L. Leng, J.P. Loria, V. Bhandari, R. Bucala, and E.J. Lolis. 2013. MIF intersubunit disulfide mutant antagonist supports activation of CD74 by endogenous MIF trimer at physiologic concentrations. Proceedings of the National Academy of Sciences. 110:10994-10999.
Lahoti, T.S., K. John, J.M. Hughes, A. Kusnadi, I.A. Murray, G. Krishnegowda, S. Amin, and G.H. Perdew. 2013. Aryl hydrocarbon receptor antagonism mitigates cytokine-mediated inflammatory signalling in primary human fibroblast-like synoviocytes. Annals of the Rheumatic Diseases. 72:1708-1716.
Kong, X., Y. Zhang, C. Liu, W. Guo, X. Li, X. Su, H. Wan, Y. Sun, and N. Lin. 2013. Anti-angiogenic effect of triptolide in rheumatoid arthritis by targeting angiogenic cascade. PloS one. 8:e77513.
Lin, N. 2013. Triptolide Prevents Bone Destruction in the Collagen-Induced Arthritis Model of Rheumatoid Arthritis by Targeting RANKL/RANK/OPG Signal Pathway. Evidence-Based Complem. & Altern. Med. 2013:Article ID 626038.
Liu, C., X. Kong, X. Li, W. Guo, C. Zhang, Y. Sun, X. Su, X. Liu, A. Lu, and N. Lin. 2013. Wen Luo Yin inhibits angiogenesis in collagen-induced arthritis rat model and in vitro. Journal of ethnopharmacology. 149:478-489.
Matsumoto, Y., H. Ichihara, M. Hino, M. Umebayashi, and R. Ueoka. 2013. Therapeutic effects of hybrid liposomes without drugs for rheumatoid arthritis. Drug Delivery:doi:10.3109/10717544.10712013.10869635.
Woo, J., M.P. Vierboom, H. Kwon, D. Chao, S. Ye, J. Li, K. Lin, I. Tang, N.A. Belmar, and T. Hartman. 2013. PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis. Arthritis research & therapy. 15:R207.
Xu, Z., G. Wu, X. Wei, X. Chen, Y. Wang, and L. Chen. 2013. Celastrol Induced DNA Damage, Cell Cycle Arrest, and Apoptosis in Human Rheumatoid Fibroblast-Like Synovial Cells. Am. Journal of Chinese Medicine. 41:615-628.
Bai, F., O.A. Asojo, P. Cirillo, M. Ciustea, M. Ledizet, P.A. Aristoff, L. Leng, R.A. Koski, T.J. Powell, R. Bucala, and K.G. Anthony. 2012. A Novel Allosteric Inhibitor of Macrophage Migration Inhibitory Factor (MIF). Journal of Biological Chemistry. 287:30653-30663.
Brys, R., N. Vangeghinste, P. Tomme, H. Johanus, and M. Klaassen. 2012. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases. Patent US 8097408 B2.
Evanko, S.P., S. Potter-Perigo, P.L. Bollyky, G.T. Nepom, and T.N. Wight. 2012. Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biology. 31:90-100.
Hepperle, M., J. Liu, R. Rowland, and D. Vitharana. 2012. Alpha carbolines and uses thereof. Patent US 8101604 B2.
Gill, D., J. Li, G. Veldman, L. Fouser, V. Valge-Archer, D. Lowe, C. Russell, S. Cohen, A. Thom and R. Miniter. Antibodies to human IL-22. Patent US 8187603 B2.
Hsu, J., Y. Gu, S.-L. Tan, S. Narula, J.A. DeMartino, and C. Liao. 2012. Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: A potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints. Immunology letters. 150:97-104.
Matsuyama., Y., H. Okazaki, M. Hoshino, S. Onishi, Y. Kamata, K. Nagatani, T. Nagashima, M. Iwamoto, T. Yoshio, H. Ohto-Ozaki, H. Tamemoto, M. Komine, H. Sekiya, S. Tominaga, and S. Minoto. 2012. Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1β signaling and a poor clinical response. Rheumatology Intl, 5:1397-1401.
Tsuji, F., K. Oh-hashi and K. Kiuchi. 2012. Differential effects of Akt pathway inhibitors on IL-1β-induced protein phosphorylation in human fibroblast-like Synoviocytes. J Receptors & Signal Transd, 32:22-28.
Valge-Archer, V., A. Williams, D. Young, M. Whitters, M. Collins and J. Witek. 2012. Nucleic acids coding for antibodies against human IL-21 receptor and uses therefor. Patent US 8143385 B2.
Yamaguchi, A., K. Nozawa, M. Fujishiro, M. Kawasaki, F. Suzuki, K. Takamori, H. Ogawa, Y. Takasaki, and I. Sekigawa. 2012a. CC motif chemokine ligand 13 is associated with rheumatoid arthritis pathogenesis. Modern Rheumatology. 23:856-863.
Yamaguchi, A., K. Nozawa, M. Fujishiro, M. Kawasaki, K. Takamori, H. Ogawa, I. Sekigawa, and Y. Takasaki. 2012b. Estrogen inhibits apoptosis and promotes CC motif chemokine ligand 13 expression on synovial fibroblasts in rheumatoid arthritis. Immunopharmacology and Immunotoxicology. 34:852-857.
Brys, R., N. Vandeghinste, and P. Tomme. 2011. Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseases. Patent US 7919259 B2.
Chen, D.P., C.K. Wong, L.S. Tam, E.K. Li, and C.W. Lam. 2011. Activation of human fibroblast-like synoviocytes by uric acid crystals in rheumatoid arthritis. Cellular & molecular immunology. 8:469-478.
Chen, D.-P., C.-K. Wong, P.-C. Leung, K.-P. Fung, C.B.-S. Lau, C.-P. Lau, E.K.-M. Li, L.-S. Tam, and C.W.-K. Lam. 2011b. Anti-inflammatory activities of Chinese herbal medicine sinomenine and Liang Miao San on tumor necrosis factor-α-activated human fibroblast-like synoviocytes in rheumatoid arthritis. Journal of ethnopharmacology. 137:457-468.
Ichihara, H., M. Hino, T. Makizono, M. Umebayashi, Y. Matsumoto, and R. Ueoka. 2011. Inhibitory effects of hybrid liposomes on the growth of synoviocyte causing rheumatoid arthritis. Bioorg. & Med. Chem. letters. 21:207-210.
Mei, Y., Y. Zheng, H. Wang, J. Gao, D. Liu, Y. Zhao, and Z. Zhang. 2011. Arsenic trioxide induces apoptosis of fibroblast-like synoviocytes and represents antiarthritis effect in experimental model of rheumatoid arthritis. The Journal of Rheumatology. 38:36-43.
Negishi, Y., Y. Tsunoda, Y. Endo-Takahashi, Y. Oda, R. Suzuki, K. Maruyama, M. Yamamoto, and Y. Aramaki. 2011. Local gene delivery system by bubble liposomes and ultrasound exposure into joint synovium. Journal of drug delivery. 2011:Article ID 203986.
Venkatesha, S.H., H. Yu, R. Rajaiah, L. Tong, and K.D. Moudgil. 2011. Celastrus-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses. Journal of Biological Chemistry. 286:15138-15146.
Baima, E.T., J.A. Guzova, S. Mathialagan, E.E. Nagiec, M.M. Hardy, L.R. Song, S.L. Bonar, R.A. Weinberg, S.R. Selness, S.S. Woodard, J. Chrencik, W.F. Hood, J.F. Schindler, N. Kishore, and G. Mbalaviele. 2010. Novel Insights into the Cellular Mechanisms of the Anti-inflammatory Effects of NF-κB Essential Modulator Binding Domain Peptides. Journal of Biological Chemistry. 285:13498-13506.
Fouser, L, M. Hegen, D.Luxenberg ad M. O’Toole. 2010. Methods of using antibodies against human IL-22. Patent US 7811567 B2.
Fujimoto, K., M. Oi, H. Hasegawa, H. Kanegae, A. Inaba, M. Tomomura and A. Touura. 2010. Inhibition of RANKL Expression in Synovial Fibroblasts of Rheumatoid Arthritis by Serum Calcium-decreasing Factor (Caldecrin). J Meikai Dent Med 39:42-51.
Hepperle, M., J. Liu, F. Soucy, Y. Ye, R. Murray, R. Prakash, J. Little, A. Castro, H. Mazdiyasni, P. Fleming, and D. Reynolds. 21010. Beta-carbolines useful for treating inflammatory disease. Patent US 7727985 B2.
Matsuyama, Y., H. Okazaki, H. Tamemoto, H. Kimura, Y. Kamata, K. Nagatani, T. Nagashima, M. Hayakawa, M. Iwamoto, and T. Yoshio. 2010. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. The Journal of rheumatology. 37:18-25.
Suzuki, M., M. Hashizume, H. Yoshida, and M. Mihara. 2010. Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int. 30:309-315.
Brys, R,. N. Vandeghinste, P. Tomme, and H. Klaassen. 2009. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases. Patent US 7485468 B2.
Itoh, Y., N. Hatano, H. Hayashi, K. Onozaki, K. Miyazawa, and K. Muraki. 2009. An environmental sensor, TRPV4 is a novel regulator of intracellular Ca2+ in human synoviocytes. American Journal of Physiology. 297:C1082-C1090.
Konomi, I., Y.I. DANTSUJI, and A. Nagayama. 2009. Characterization of a Persistent Chlamydial Infection and the Role of Toll like Receptors in the IL 6 Secretion in Chlamydia Trachomatis Infected Human Synovial Fibroblasts. Fukuoka Daigaku igaku kiyō. 36:205-214.
Laurent, A., M. Proulx, and J. Jaquith. 2009. Functionalized pyrrolidines and use thereof as iap inhibitors. Patent Application US 20110117081 A1.
Yamaura, M., M. Yao, I. Yaroslavsky, R. Cohen, M. Smotrich, and I.E. Kochevar. 2009. Low level light effects on inflammatory cytokine production by rheumatoid arthritis synoviocytes. Lasers in surgery and medicine. 41:282-290.
Furuhashi, I., K. Abe, T. Sato, and H. Inoue. 2008. Thrombin-stimulated proliferation of cultured human synovial fibroblasts through proteolytic activation of proteinase-activated receptor-1. J. of pharmacological sciences. 108:104-111.
Hashizume, M., N. Hayakawa, and M. Mihara. 2008. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17. Rheumatology. 47:1635-1640.
Hicks, F., M. Cooper, and A. Brown. 2008. Salts of an IKK inhibitor. Patent Application US 20090131422 A1.
Morita, K., T. Niwa, K. Ichikawa, and H. Yoshida. 2008. Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor. Patent Application US 20100209490 A1.
Morita, K., T. Niwa, Y Kasuya, K. Ichikawa, and H. Yoshida. 2008. Antibodies modified with hydrophobic molecule. Patent Application US 20110269942 A1.
Hall, J.P., Y. Kurdi, S. Hsu, J. Cuozzo, J. Liu, J.-B. Telliez, K.J. Seidl, A. Winkler, Y. Hu, and N. Green. 2007. Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. Journal of Biological Chemistry. 282:33295-33304.
Abe, K., A. Aslam, A.F. Walls, T. Sato, and H. Inoue. 2006. Up-regulation of protease-activated receptor-2 by bFGF in cultured human synovial fibroblasts. Life sciences. 79:898-904.
Lu, J., N. Zhi, S. Wong, and K.E. Brown. 2006. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. Journal of Infectious Diseases. 193:582-590.
Nakajima, T., Y. Kato, T. Yamadera, and T. Amano. 2006. Therapeutic Agent for Cancer Comprising Substance Capable of Inhibiting Expression or Function of Synoviolin as Active Ingredient and Screening Method for the Therapeutic Agent for Cancer. Patent Application US 20080305102 A1.
Perper, S., B. Browning, L. Burkly, S. Weng, C. Gao, K. Giza, L. Su, L. Tarilonte, T. Crowell, L. Rajman, L. Runkel, M. Scott, G. Atkins, D. Findlay, T. Zheng, and H Hess. 2006. TWEAK Is a Novel Arthritogenic Mediator. J Immunol. 15:2610-2620.
Akasaka, Y., K. Abe, T. Sato, and H. Inoue. 2005. Regulation of neurokinin-1 receptor messenger RNA expression in synovial fibroblasts of patients with rheumatoid arthritis. Neuropeptides. 39:467-474.
Keith, J.C., Jr., L.M. Albert, Y. Leathurby, M. Follettie, L. Wang, L. Borges-Marcucci, C.C. Chadwick, R.J. Steffan, and D.C. Harnish. 2005. The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritis. Arthritis research & therapy. 7:R427-438.
Bernier, S.G., D.D. Lazarus, E. Clark, B. Doyle, M.T. Labenski, C.D. Thompson, W.F. Westlin, and G. Hannig. 2004. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America. 101:10768-10773.
Arts, G.-J., E. Langemeijer, R. Tissingh, L. Ma, H. Pavliska, K. Dokic, R. Dooijes, E. Mešić, R. Clasen, and F. Michiels. 2003. Adenoviral vectors expressing siRNAs for discovery and validation of gene function. Genome res. 13:2325-2332.
Lin, B., J.M. Kidder, R. Noring, A.C. Steere, M.S. Klempner, and L.T. Hu. 2001. Differences in Synovial Fluid Levels of Matrix Metalloproteinases Suggest Separate Mechanisms of Pathogenesis in Lyme Arthritis before and after Antibiotic Treatment. Journal of Infectious Diseases. 184:174-180.
Privat, S.J., A. Oo, and L.D. Waterbury. 2001. Production of interleukin-6, but not interleukin-8, induced by TNF-alpha or IL-1 beta in human fibroblast-like synoviocyte increases over cell passage. Proceedings of the Western Pharmacology Society. 44:9-13.
Yano, K., N. Nakagawa, H. Yasuda, E. Tsuda, and K. Higashio. 2001. Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. Journal of bone and mineral metabolism. 19:365-372.